Director or Sr. Director, DMPK

Sorry, this job was removed at 06:20 p.m. (CST) on Friday, Apr 10, 2026
Be an Early Applicant
Watertown, MA, USA
In-Office
Healthtech • Biotech • Pharmaceutical
The Role
Who we are:

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn. 


How we work:
  • PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
  • COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
  • BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.

How you’ll make an impact:

You will be accountable to set DMPK strategy and drive execution to advance projects from early discovery through preclinical development, and will seamlessly partner with all line functions represented on project teams. Your deep expertise in PK/ADME strategies and tactics in beyond Ro5 small molecule drug discovery and preclinical development is foundational, as is hands-on experiences in PK and PK/PD modeling, and human PK, dose, and DDI predictions. You will thrive in a collaborative, past-paced, interdisciplinary team environment.

  • Represent DMPK function as core project team member across multiple high profile programs in our Immunology franchise. Accountability for all aspects of DMPK support. Planning, stewardship, analysis, and integration of all in In Vitro and In Vivo ADME, PK, and PK/PD efforts in support of discovery and preclinical development programs.
  • Outstanding, proactive collaboration with all team functions (Pharmacology, Toxicology, Pharm. Sci., Form. Dev., Chemistry, Translational Medicine, Clin. Pharm.) to secure effective advancement of Kymera’s projects and portfolio. Influence wider project strategy and team decision making.
  • Conduct PK and PK/PD modeling, provide predicted human PK and efficacious dose projections and DDI risk assessment.
  • Design and implementation of DMPK strategies for NCE optimization and characterization in collaboration with PCD peers, and project and other functional stakeholders.
  • Manage interactions with CROs to ensure high quality and on-time execution of DMPK studies.
  • Author and review relevant sections of regulatory documents.
  • Contribute to Kymera’s internal and external presentation/publication strategy.

Skills and experience you’ll bring:
  • MSc or PhD in Drug Metabolism, Pharmacokinetics, Pharmaceutical Sciences, Pharmacology, or related disciplines.
  • 15+ years (with MSc) or at least 10 years (with PhD) of relevant experience in the Pharmaceutical/Biotech industry.
  • Prior experience as a core DMPK project team representative on a multifunctional team is critically required, previous supervisory/managerial experience of DMPK project representatives and/or accountability for DMPK on a project portfolio is ideal.
  • In-depth understanding and strategic application of all PK/ADME assays, methods and models. Ability to distill critical information, develop structure-property relationships, clear strategic guidance & effective communication in support of effective multi-parametric NCE optimization.
  • Strong understanding of DMPK, PK/PD modeling, human PK, efficacious dose, and DDI prediction strategies, incl. all required input from adjacent functions.
  • Expertise in managing CROs, robust knowledge of relevant regulatory guidances.
  • Proficiency in Phoenix WinNonlin desired. Experiences with PBPK modeling are a plus.
  • Passion for data driven analysis, and strongly developed business-of-science thinking.
  • Excellence in analytical, organizational, and communication skills.
  • Ability to thrive in a fast-paced, highly matrixed environment.

                                                                                                                                                                                


Equal Employment Opportunity

Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.


Compensation

  • Kymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.
  • The anticipated base salary range for this role is $195,000 – $330,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.
  • Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate’s depth of experience and the capabilities they bring to the position.


Kymera Therapeutics Compensation & Benefits Highlights

The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Kymera Therapeutics and has not been reviewed or approved by Kymera Therapeutics.

  • Fair & Transparent Compensation Pay is considered market‑competitive for core scientific and leadership roles, with clearly posted ranges visible for U.S. openings. Feedback suggests strong base pay aligns with comments about high salary and good pay.
  • Equity Value & Accessibility Employees are eligible to participate in broad‑based equity programs, including an equity incentive plan and an ESPP. Feedback suggests this ownership opportunity can meaningfully augment total compensation in a growth‑focused setting.
  • Leave & Time Off Breadth Company‑wide office shutdowns, standard PTO, and summer schedules are promoted to help people unplug. Feedback suggests these practices contribute to a well‑rounded time‑off offering.

Kymera Therapeutics Insights

Similar Jobs

In-Office
Boston, MA, USA
447 Employees
222K-272K Annually

Circle Logo Circle

Senior Counsel

Blockchain • Fintech • Payments • Financial Services • Cryptocurrency • Web3
In-Office or Remote
26 Locations
1050 Employees
230K-298K Annually

DraftKings Logo DraftKings

Senior Product Manager

Digital Media • Gaming • Information Technology • Software • Sports • Esports • Big Data Analytics
Hybrid
Boston, MA, USA
6400 Employees
136K-170K Annually

General Motors Logo General Motors

Chevrolet Zone Manager Parts and Service

Automotive • Big Data • Information Technology • Robotics • Software • Transportation • Manufacturing
Remote or Hybrid
United States
165000 Employees
140K-187K Annually
Get Personalized Job Insights.
Our AI-powered fit analysis compares your resume with a job listing so you know if your skills & experience align.

The Company
Watertown, Massachusetts
208 Employees
Year Founded: 2016

What We Do

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years

Similar Companies Hiring

Camber Thumbnail
Fintech • Healthtech • Social Impact
New York, New York
90 Employees
Sailor Health Thumbnail
Healthtech • Social Impact • Telehealth
New York City, NY
20 Employees
Granted Thumbnail
Mobile • Insurance • Healthtech • Financial Services • Artificial Intelligence
New York, New York
23 Employees

Sign up now Access later

Create Free Account

Please log in or sign up to report this job.

Create Free Account